<DOC>
	<DOCNO>NCT02589652</DOCNO>
	<brief_summary>This multicenter , prospective cohort study evaluate efficacy safety sequential combination switch therapy pegylated interferon alfa-2a chronic hepatitis B patient low HBsAg HBeAg titer long-term entecavir therapy , compare continue ETV therapy .</brief_summary>
	<brief_title>Switch Sequential Combination Therapy Peginterferon Hepatitis B Patients With Longterm Entecavir Therapy</brief_title>
	<detailed_description>Chronic hepatitis B ( CHB ) infection remain global health treat . The ideal end point therapy HBsAg loss HBsAg seroconversion , indicate complete remission CHB . In patient HBeAg-positive CHB , sustain HBeAg seroconversion also desirable end point . Current therapy include pegylated interferon ( PegIFN ) finite nucleos ( ) ide analogue ( NUCs ) longterm therapy . However , 30-40 % patient may achieve HBeAg seroconversion PegIFN monotherapy , whereas 15-20 % patient entecavir ( ETV ) . Recently , accumulate evidence show optimization switch combine PegIFN patient long-term ETV therapy may increase rate HBeAg seroconversion even lead complete eradication HBV . However , two regimen test adequately patient low HBsAg/HBeAg titer long-term ETV therapy . This multicenter , prospective cohort study evaluate efficacy safety sequential combination switch therapy pegylated interferon alfa-2a chronic hepatitis B patient low HBsAg HBeAg titer long-term entecavir therapy , compare continue ETV therapy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Male female patient &gt; 18 ≤ 60 year age ; Positive HBsAg 6 month ; Patients receive previous ETV therapy ≥2 year ; Patients achieve undetectable HBV DNA , HBsAg &lt; 1500IU/mL HBeAg &lt; 200S/CO prior switch SC therapy ; ALT &lt; =10*ULN TB &lt; 2*ULN ; Patients assign treatment PegIFN ( SC switch ) continuous ETV previous ETV therapy Evidence decompensated cirrhosis hepatocellular carcinoma ; Serological evidence coinfection HCV , HDV HIV ; Pregnant breastfeed woman ; Patients diseases might contraindicate PegIFN therapy include severe psychiatric disease , immunological disease , severe retinopathy , thyroid dysfunction , leukocytopenia , thrombopenia , etc Patients receive concomitant therapy telbivudine ; A history drug alcohol abuse ; Other condition investigates consider suitable participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Pegylated interferon</keyword>
	<keyword>Entecavir</keyword>
</DOC>